Torrent Pharmaceuticals Limited has received a corrigendum order from the National Company Law Tribunal (NCLT) Ahmedabad Bench regarding its proposed amalgamation with J.B. Chemicals & Pharmaceuticals Limited. The tribunal issued the corrigendum order on March 24, 2026, which was subsequently uploaded to the NCLT website on March 25, 2026.

Latest NCLT Developments

The corrigendum order represents a follow-up to the initial tribunal order that was uploaded on March 23, 2026. This latest development indicates ongoing procedural progress in the amalgamation process between the two pharmaceutical companies.

Official Communication Timeline

Torrent Pharmaceuticals filed an official intimation on March 25, 2026, with both BSE Limited and National Stock Exchange of India Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Chintan Trivedi, Company Secretary, ensuring proper regulatory compliance.

Amalgamation Structure

Under the proposed Scheme of Amalgamation, J.B. Chemicals & Pharmaceuticals Limited will serve as the transferor company, while Torrent Pharmaceuticals Limited will act as the transferee company. This structure indicates that J.B. Chemicals will be merged into Torrent Pharmaceuticals.

Previous Communications

The company referenced its earlier intimation dated March 24, 2026, regarding the initial order passed by the NCLT Ahmedabad Bench. The current corrigendum order represents a continuation and clarification of that earlier tribunal decision, demonstrating ongoing progress in the regulatory approval process.

Regulatory Compliance

The intimation ensures proper disclosure to stock exchanges and investors, maintaining transparency with all relevant stakeholders. The communication was addressed to both BSE Limited and National Stock Exchange of India Limited, with the company indicating that this information is provided for the records of the stock exchanges and relevant parties involved in monitoring the amalgamation process.

Torrent Pharmaceuticals has officially announced the launch of its semaglutide brands - Sembolic and Semalix - in India, offering both oral and injectable formulations. The company has achieved the distinction of being the first Indian pharmaceutical company to launch generic oral semaglutide, marking a significant milestone in India's diabetes and obesity treatment landscape.

Product Launch Details

The pharmaceutical company has introduced two branded formulations of semaglutide to address the growing need for metabolic disorder treatments:

Leadership Perspective

Amal Kelshikar, CEO – India Business at Torrent Pharma, emphasized the significance of this launch: "Metabolic disorders represent one of the most significant healthcare challenges in India with a significant portion of our population affected by Type-2 Diabetes. Our entry into the GLP-1 therapy segment reflects Torrent's commitment to expanding treatment options available to healthcare professionals managing complex metabolic conditions at affordable prices."

GLP-1 Therapy Segment

The launch expands Torrent's presence in the GLP-1 (glucagon-like peptide-1) receptor agonist category, which represents well-established prescription medications for managing type 2 diabetes and obesity. These medications work by enhancing insulin secretion, reducing glucagon levels, and helping regulate appetite. They have demonstrated effectiveness in decreasing haemoglobin A1c (HbA1c), promoting weight loss, and reducing cardiovascular event risks.

Company Profile

Torrent Pharmaceuticals operates as the flagship company of the Torrent Group, with annual revenues exceeding ₹11,500 crores and group revenues of approximately ₹45,000 crores. Following the JB Pharma acquisition, the company ranks 5th in the Indian Pharmaceuticals Market and maintains top 5 positions in cardiovascular, gastro intestinal, central nervous system, pain management, and cosmo-dermatology therapeutic segments.

The company maintains a specialty-focused approach with approximately 76% of its India revenues derived from chronic and sub-chronic therapies, while establishing itself as the number 1 Indian pharma company in Brazil and Germany.